SBFM Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Sunshine Biopharma (NASDAQ: SBFM)
›
Sunshine Biopharma (NASDAQ: SBFM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 50 employees.
The shares were at 2.700 USD on 13 November 2026, down 99.2% over 52 weeks. Its 52-week range is 2.530 USD to 464.00 USD: the price is 99.4% below the high and 6.7% above the low.
Its market capitalisation is 2.05M USD.
Sunshine Biopharma reports return on equity of -25.9%, an operating margin of -14.7% and revenue down 1.6% year over year.
It holds more cash than debt, a net cash position of 13.35M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.